Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Draft Guidance: How To Claim Humanitarian Device Status

This article was originally published in The Gray Sheet

Executive Summary

Firms must document that humanitarian devices target a rare disease or condition, or a small subset of a common disease or condition, the draft explains.

You may also be interested in...



CVRx’s Hypertension Implant Gains FDA Humanitarian Exemption

The humanitarian device exemption for the Barostim neo legacy implantable electronic stimulator for hypertension is CVRx’ first commercial approval in the U.S. The Minneapolis company is also developing the Barostim therapy for treatment of heart failure

Regulatory News In Brief

New guidance, rules and more from FDA and Congress.

Senate Draft Bill Compromises On Profit Incentive For Humanitarian Devices

More devices approved under a humanitarian device exemption could be priced for profit if draft Senate language is enacted, but restrictions are included to ensure that current pediatric incentives are not gutted.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel